S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:PTGX

Protagonist Therapeutics Stock Forecast, Price & News

$30.12
-0.85 (-2.74 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.81
$31.05
50-Day Range
$12.95
$49.69
52-Week Range
$12.80
$50.54
Volume996,055 shs
Average Volume860,292 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56
30 days | 90 days | 365 days | Advanced Chart
Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Protagonist Therapeutics logo

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Employees
79
Year Founded
N/A

Sales & Book Value

Annual Sales
$28.63 million
Book Value
$7.31 per share

Profitability

Net Income
$-66.15 million
Net Margins
-299.39%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.43 billion
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.02 out of 5 stars

Medical Sector

574th out of 1,361 stocks

Pharmaceutical Preparations Industry

269th out of 668 stocks

Analyst Opinion: 4.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

Is Protagonist Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Protagonist Therapeutics stock.
View analyst ratings for Protagonist Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Protagonist Therapeutics?

Wall Street analysts have given Protagonist Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protagonist Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 3,640,000 shares, an increase of 27.3% from the September 15th total of 2,860,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 8.7% of the company's shares are sold short.
View Protagonist Therapeutics' Short Interest
.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Protagonist Therapeutics
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its earnings results on Wednesday, August, 4th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.14. The company earned $2.27 million during the quarter, compared to the consensus estimate of $5.60 million. Protagonist Therapeutics had a negative net margin of 299.39% and a negative trailing twelve-month return on equity of 30.58%.
View Protagonist Therapeutics' earnings history
.

How has Protagonist Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 320.7% and is now trading at $30.12.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PTGX?

7 brokers have issued 12 month target prices for Protagonist Therapeutics' stock. Their forecasts range from $40.00 to $93.00. On average, they expect Protagonist Therapeutics' share price to reach $56.75 in the next year. This suggests a possible upside of 88.4% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dinesh V. Patel, President, Chief Executive Officer & Director
  • Donald A. Kalkofen, Chief Financial Officer
  • Mark L. Smythe, Vice President-Technology
  • David Y. Liu, Chief Scientific Officer (LinkedIn Profile)
  • Samuel R. Saks, Chief Medical Officer

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $30.12.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics has a market capitalization of $1.43 billion and generates $28.63 million in revenue each year. The company earns $-66.15 million in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

Protagonist Therapeutics employs 79 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

Where are Protagonist Therapeutics' headquarters?

Protagonist Therapeutics is headquartered at 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at (510) 474-0170 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.